Entero Healthcare Solutions Ltd

- Entero Healthcare Solutions currently has room to take additional debt, primarily to support working capital requirements. - The company plans to balance the use of debt and equity for financing, keeping an eye on interest costs and debt-equity ratios. - Post-IPO, with a stronger balance sheet, the company intends to be more aggressive in pursuing acquisitions, implying potential future equity or debt fundraising. - No specific new fundraising through debt or equity has been announced, but they are focused on leveraging available capital efficiently to drive growth. - IPO proceeds of approx. Rs. 951 crores are allocated for working capital, inorganic growth including acquisitions, and repayment of borrowings in FY '25. Overall, while no immediate new fundraising is declared, Entero remains open to using both debt and equity as needed for growth and acquisitions.

- Entero Healthcare plans to utilize IPO proceeds (net Rs. 951 crores) primarily for: - Working capital (about Rs. 250 crores in FY '25) - Pursuing growth opportunities, including inorganic growth (about Rs. 177 crores in FY '25) - General corporate purposes (about Rs. 48 crores in FY '25) - The company is actively looking for acquisition opportunities and has signed several term sheets, aiming to convert these into actual acquisitions to expand their network geographically and into new product segments. - No specific mention of major capital expenditure projects beyond acquisitions; focus is primarily on strategic investments via acquisitions and scaling existing operations. - The acquisition strategy targets mostly smaller distributors to expand presence in under-served areas. - The company aims to leverage capital raised to accelerate both organic growth and inorganic (acquisition-led) growth.

- Entero Healthcare targets approximately 20% organic revenue growth annually, supported by both organic expansion and strategic acquisitions. - The company has a track record of doubling sales over the past two years and sees a fair possibility of repeating this in the next two years. - They expect to complement organic growth with aggressive inorganic growth post-IPO, leveraging a stronger balance sheet. - Historically, Entero has achieved a 22% organic growth rate, with a total CAGR of 36% over the past few years including acquisitions. - Acquisitions have been a key driver, with 34 completed over five years, helping expand geographic reach and product portfolio. - The organized distribution market share is expected to rise from current single digits to 20-30% over five years, providing additional growth opportunities. - Overall growth levers include expanding customer base, product portfolio, geographic penetration, and leveraging technology.

- Targeting EBITDA margin expansion from current ~3% to over 5% in the next 2-3 years through scale, procurement efficiencies, private label growth, value-added services, and operating leverage. - Organic revenue growth target is ~20% annually, aiming to maintain approximately 2x industry growth rate. - Inorganic growth through acquisitions will complement organic growth, with plans to accelerate acquisitions post-IPO due to a stronger balance sheet. - Longer-term EBITDA margins could exceed 5% as market share strengthens, procurement efficiencies improve, and private label share increases. - ROCE expected to improve above 20% over the next 2-3 years by expanding operating margins and enhancing capital efficiency. - Profit after tax showed strong improvement, with 9 months FY '24 PAT at Rs. 19 crores vs. loss in previous year. - No specific revenue or EPS figures were disclosed for FY '24 or FY '25, but growth and margin expansion guidance were provided.

The transcript provided does not contain specific information on Entero Healthcare Solutions Limited's current or expected orderbook or pending orders. The discussion primarily focuses on topics such as: - Business growth strategy and consolidation in pharmaceutical distribution - Acquisition plans and inorganic growth opportunities - Margin improvement levers and scale benefits - Financial performance commentary and IPO proceeds utilization - Market share and industry growth targets No direct mention or data related to orderbook size, expected orders, or pending orders was found in the available pages.